TGTX TG Therapeutics (TGTX) Q4 FY25 earnings call
TG Therapeutics delivered a strong Q4 and full-year 2025, driven by robust BRIUMVI sales and market share gains in the relapsing multiple sclerosis (RMS) market. The company is advancing its pipeline with ENHANCE and subcutaneous BRIUMVI programs, aiming to simplify treatment and expand market opportunity. Management reaffirmed its full-year 2026 revenue guidance, balancing strong demand with typical Q1 seasonal headwinds, and emphasized a flexible capital allocation strategy focused on maximizing BRIUMVI, judicious pipeline expansion, and share repurchases.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
Inve summary of the company's earnings call; see how call summaries are prepared. Not investment advice.